Maven Clinic, a women's health startup, secures $1.7 billion in funding at a valuation of $1.7 billion.

• On Tuesday, Maven Clinic declared that it had raised $125 million in a funding round at a valuation of $1.7 billion.
• The startup aims to offer virtual care for women and families throughout their reproductive journey.
• Maven is a three-time CNBC Disruptor 50 member.

A $125 million funding round has been closed by Maven Clinic, a health-care startup for women and families, at a valuation of $1.7 billion.

Maven aims to provide virtual care to patients throughout their reproductive journey, from planning a family to menopause. The company has raised over $425 million and will use the funds to enhance its fertility benefits, expand its platform, and utilize real-time data to offer more proactive care to its members.

In 2014, Kate Ryder founded Maven, a company that provides support to families while building their lives, after observing her friends' struggles. Today, Maven covers approximately 17 million lives through its contracts with health plans and employers, including companies such as , and .

Ryder informed CNBC that digital health is still in its infancy.

Maven, a U.S. startup focused on women's and family health, became the first to achieve "unicorn" status with a valuation of over $1 billion. Its investors include General Catalyst, Sequoia, Oak HC/FT, and celebrities such as Oprah Winfrey, Mindy Kaling, and Reese Witherspoon.

Maven is currently concentrating on its product roadmap, but Ryder stated that the company eventually plans to go public. For the past three years, Maven has been included on the CNBC Disruptor 50 list.

The upcoming election between Vice President Kamala Harris and former President Donald Trump has made women's health, particularly reproductive health, a contentious issue. Ryder stated that Maven is willing to share its data and viewpoint on policy, regardless of which administration emerges victorious.

In the wake of the U.S. Supreme Court's decision to overturn Roe v. Wade in June 2022, Maven emerged as a key resource for employers seeking guidance on navigating the new landscape of healthcare. Ryder characterized the ruling as a "devastating step back for healthcare in the United States" in a blog post, emphasizing that Maven could help clients reimburse patients for travel across state lines.

Following the ruling, there was a 67% increase in interest in travel benefits and health-care for pregnant people among the company's customers.

During the same year, venture investments in women's health companies increased by 5%, according to a February report from Deloitte. Maven raised $90 million in funding in November. However, the report noted that venture funding for the overall health tech market decreased by 27% during the same period.

The availability of data on women's health is increasing, thanks to companies like Maven. In a post-Roe world, Ryder observes that the information is often discouraging, particularly as experts are gaining a clearer understanding of the preventable deaths resulting from limited access to care.

""Between increased funding and research, as well as more data points from states and platforms like ourselves, we can create a comprehensive picture to improve policy, but the question is, how long must people continue to suffer needlessly in the meantime?" Ryder posed."